Natera, Inc. (NTRA)

Market Cap	28.28B +27.9%
Revenue (ttm)	2.12B +38.2%
Net Income	-309.19M
EPS	-2.29
Shares Out	138.32M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	351,008
Open	204.53
Previous Close	205.61
Day's Range	203.67 - 209.76
52-Week Range	125.38 - 256.36
Beta	1.63
Analysts	Strong Buy
Price Target	253.79 (+24.14%)
Earnings Date	Feb 26, 2026

About NTRA

Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissu...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jul 2, 2015
• Employees: 4,434
• Stock Exchange: NASDAQ
• Ticker Symbol: NTRA
• Website: https://www.natera.com

Financial Performance

In 2024, Natera's revenue was $1.70 billion, an increase of 56.75% compared to the previous year's $1.08 billion. Losses were -$190.43 million, -56.20% less than in 2023.

Analyst Summary

According to 14 analysts, the average rating for NTRA stock is "Strong Buy." The 12-month stock price target is $253.79, which is an increase of 24.14% from the latest price.

Price Target

$253.79

(24.14% upside)

Analyst Consensus: Strong Buy